Among trials evaluating higher daily doses of ASA versus no-ASA, the relative reduction in vascular events was 19% with doses of 500 to 1500 mg daily, 26% with doses of 160 to 325 mg daily, and 32% ...

Expert Rev Clin Pharmacol. 2013;6(3):271-288. All FDA-approved migraine treatments are approved only for adults. No migraine products have officially been approved for use in children. Other types ...

Doodipala Samba Reddy Disclosures Expert Rev Clin Pharmacol. 2013;6 (3):271-288.